摘要
目的探讨依达拉奉联合脑苷肌肽治疗重症颅脑损伤患者的效果。方法选取我院2014年1月至2018年7月收治的重症颅脑损伤患者352例,随机分为联合组和对照组,各176例。联合组给予依达拉奉联合脑苷肌肽治疗,对照组给予脑苷肌肽治疗。观察两组患者治疗前后的GCS评分、 ICP、颅脑损伤标记物(S-100B、 GFAP、 NSE、 UCH-L1)水平及不良反应情况。结果治疗后,两组患者的GCS评分显著高于治疗前,且联合组的GCS评分显著高于对照组(P均<0.05)。治疗后,两组患者的ICP、颅脑损伤标记物水平显著低于治疗前,且联合组的ICP、颅脑损伤标记物水平显著低于对照组(P均<0.05)。两组患者的不良反应发生率比较差异无统计学意义(P>0.05)。结论依达拉奉联合脑苷肌肽治疗重症颅脑损伤可显著提高患者的GCS评分,降低ICP,改善颅脑损伤,且安全性好,值得推广应用。
Objective To explore the effect of edaravone combined with cerebroside carnosine in the treatment of patients with severe craniocerebral injury. Methods 352 cases of patients with severe craniocerebral injury admitted to our hospital from January 2014 to July 2018 were selected and randomly divided into combined group and control group, with 176 cases in each group. The combined group was treated with edaravone combined with cerebroside carnosine, while the control group was treated with cerebroside carnosine. The GCS scores, ICP and levels of craniocerebral injury markers(S-100 B, GFAP, NSE, UCH-L1) before and after treatment, and adverse reactions of the two groups were observed. Restults After treatment, the GCS scores of two groups were significantly higher than those before treatment,and the GCS score of the combined group was significantly higher than that of the control group(all P<0.05). After treatment, the ICP and levels of craniocerebral injury markers of two groups were significantly lower than those before treatment, and the ICP and levels of craniocerebral injury markers of the combined group were significantly lower than those of the control group(all P<0.05). No statistical diffference was found in the incidence of adverse reactions between the two groups(P >0.05). Conclusions Edaravone combined with cerebroside carnosine in the treatment of severe craniocerebral injury can significantly improve patients’ GCS score, reduce the ICP, and improve the brain injury with good safety, which is worthy of promotion and application.
作者
陈同
黄解元
陈小曼
CHEN Tong;HUANG Jieyuan;CHEN Xiaoman(Department of Craniocerebral Surgery, Leizhou People's Hospital, Leizhou 524200, China)
出处
《临床医学工程》
2019年第5期613-614,共2页
Clinical Medicine & Engineering
基金
湛江市科技计划项目(项目编号:2018B101)
关键词
依达拉奉
重症颅脑损伤
脑苷肌肽
GCS评分
Edaravone
Severe craniocerebral injury
Cerebroside carnosine
GCS score
